Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Oct;173(2):422-424.
doi: 10.1111/imm.13831. Epub 2024 Jul 23.

SOX17 orchestrates immune evasion in early colorectal adenomas and cancers

Bo Pei  1   2 , Huiye Yang  3 , Fuxiang Zhou  1
Affiliations
Free article
Comment

SOX17 orchestrates immune evasion in early colorectal adenomas and cancers

Bo Pei et al. Immunology. 2024 Oct.
Free article
No abstract available

Keywords: SOX17; colorectal cancer; immune evasion; immunotherapy; mechanism.

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Goto N, Westcott PMK, Goto S, Imada S, Taylor MS, Eng G, et al. SOX17 enables immune evasion of early colorectal adenomas and cancers. Nature. 2024;627(8004):636–645.
    1. Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72(2):338–344.
    1. Subtil B, Cambi A, Tauriello DVF, de Vries IJM. The therapeutic potential of tackling tumor‐induced dendritic cell dysfunction in colorectal cancer. Front Immunol. 2021;12:724883.
    1. Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. KEYNOTE‐177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability‐high or mismatch repair‐deficient metastatic colorectal cancer (KEYNOTE‐177): final analysis of a randomised, open‐label, phase 3 study. Lancet Oncol. 2022;23(5):659–670.
    1. Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, et al. First‐line Nivolumab plus low‐dose Ipilimumab for microsatellite instability‐high/mismatch repair‐deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol. 2022;40(2):161–170.

Publication types

Substances

LinkOut - more resources